Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
EMERYVILLE, Calif., Oct. 31, 2016 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter ended September 30, 2016 after the market close, and will host a corporate update conference call and webcast on Monday, November 7, at 4:30 PM Eastern Time.
| Monday, November 7 @ 4:30 PM Eastern Time/1:30 PM Pacific Time | |
| Toll Free: | 877-675-4749 |
| International: | 719-325-4826 |
| Conference ID: | 1385531 |
| Webcast: | http://public.viavid.com/index.php?id=121629 |
| Replays, available through November 21: | |
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Replay PIN: | 1385531 |
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
